Wolverine Asset Management’s Drugs Made In America Acquisition Corp Units DMAAU Stock Holding History

Wolverine Asset Management’s Portfolio DMAAU Stock Details DMAAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-130,000	Closed	-$1.37M	–	1957
2025 Q4	$1.37M	Hold	130,000	–	–	0.01%	707
2025 Q3	$1.35M	Hold	130,000	–	–	0.01%	670
2025 Q2	$1.34M	Hold	130,000	–	–	0.01%	627
2025 Q1	$1.32M	Buy	+130,000	New	+$1.31M	0.02%	607

Other funds holding DMAAU

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wolverine Asset Management's DMAAU Position: Q1 2026 in Review

Wolverine Asset Management sold out of Drugs Made In America Acquisition Corp Units (DMAAU) in Q1 2026, closing a stake of 130,000 shares — an estimated $1.37M sold.

Wolverine Asset Management first reported a position in DMAAU in Q1 2025 and held it in 4 quarters. The position peaked at $1.37M in Q4 2025. 2 funds tracked by Wall St. Rank hold DMAAU as of Q1 2026.

Wolverine Asset Management reported no remaining Drugs Made In America Acquisition Corp Units position as of Q1 2026 after selling out during the quarter.
Wolverine Asset Management sold 130,000 Drugs Made In America Acquisition Corp Units shares in Q1 2026, an estimated $1.37M.
Wolverine Asset Management first reported a position in Drugs Made In America Acquisition Corp Units in Q1 2025 and held it in 4 quarters.
Wolverine Asset Management's Drugs Made In America Acquisition Corp Units position peaked at $1.37M in Q4 2025.
2 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Units as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.